louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05968196: Hürthle Cell Carcinoma and Follicular Thyroid Carcinoma
Official title: Clinicopathological Characteristics of Hürthle Cell Carcinoma and Follicular Thyroid Carcinoma Without Completion Thyroidectomy
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Huerthle Cell Carcinoma
Lead sponsor: The Catholic University of Korea
Sponsor class: OTHER
First posted: 2023-08-01
Enrollment: 221
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients in FTC and HCC who underwent thyroid lobectomy

Brief summary: The goal of this retrospective study is to evaluate in patients with HCC and FTC who underwent lobectomy. The main questions it aims to answer are:

* The necessity of completion thyroidectomy based on the clinicopathological characteristics
* Prognosis Participants underwent thyroid lobectomy Researchers compared HCC and FTC groups to see the prognosis after lobectomy.

Detailed description: Background The prognosis of Hürthle cell carcinoma (HCC) and follicular thyroid carcinoma (FTC) is poorly understood. These types of cancers are usually confirmed after diagnostic lobectomy. We aimed to evaluate the clinicopathological characteristics and prognoses of patients with HCC and FTC who did not undergo completion thyroidectomy.

Materials and Methods We screened 221 patients diagnosed with FTC or HCC after thyroid lobectomy at Yonsei Severance Hospital between January 2000 and December 2020. After excluding patients who underwent complete thyroidectomy, 184 patients with FTC and 37 patients with HCC were included.

Eligibility criteria: Inclusion Criteria:

* Follicular thyroid carcinoma
* Hurthle cell carcinoma
* Lobectomy

Exclusion Criteria:

* Completion thyroidectomy
* Total thyroidectomy

Primary outcomes:
measure: Disease-free survival (DFS)
timeFrame: From January 2000 to March 2023
Secondary outcomes:
measure: TNM stage
timeFrame: From January 2000 to March 2023
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06337396: Omic Approaches to Neurodevelopmental Disabilities
Official title: Omic Approaches to Characterize the Functional and Phenotypic Consequences of Rare Structural Genomic Variants in Neurodevelopmental Disabilities and Congenital Anomalies
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Neurodevelopmental Disorders
Keywords: whole genome sequencing
transcriptome analysis
genotype phenotype
structural variants
Lead sponsor: IRCCS Eugenio Medea
Sponsor class: OTHER
First posted: 2024-03-29
Enrollment: 22
Sex: ALL
Minimum age (years): 4
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: to bridge the gap between the molecular structure of CNV and the effect on the phenotype, considering NDDs as complex diseases, as they are a consequence of the imbalance in several dosage-sensitive genes, we might try to approach them through different --omics investigations (genomics, epigenomics, transcriptomics) according to the emerging field of network medicine. This holistic can provide valuable insight into understanding peculiar molecular mechanisms and unsuspected molecular interactions that contribute to the pathogenesis of the condition and possibly pave the way for uncovering new drug strategies that even if they do not heal the patient may improve his performance and the social interaction


Eligibility criteria: Inclusion Criteria:

Patients with neurodevelopmental disorders carrying a genomic rearrangement identified through chromosomal microarray analysis (CMA)

Exclusion Criteria:

NA

Primary outcomes:
measure: Number of likely pathogenic structural variants
timeFrame: once at recruitment
measure: Number of patients for whom a genotype-phenotype correlation is found
timeFrame: once at recruitment
Secondary outcomes:
Other outcomes:
Locations:
city: Bosisio Parini
country: Italy
facility: Scientific Institute IRCCS Eugenio Medea
state: LC
Study officials:
References:
Clinical trial NCT00938496: Non-Interventional Study of Zoladex in Endometriosis
Official title: A Non-interventional Study of Postoperative Treatment With Goserelin Acetate (Zoladex) in Moderate to Severe Endometriosis Patient
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Endometriosis
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2009-07-14
Enrollment: 408
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Study Population Description: Patient with advanced endometriosis confirmed histological (r-AFS score III-IV) with conservative laparoscopy or laparotomy has the indication of Zoladex and has already been prescribed Zoladex according to physician's judgment, irrespective of the inclusion in the study

Brief summary: This is a prospective, open label NIS, which is to assess the efficacy of Zoladex in adjuvant setting after operation in moderate to severe endometriosis patients.


Eligibility criteria: Inclusion Criteria:

* Advanced endometriosis confirmed histologically (r-AFS score III-IV) with conservative laparoscopy or laparotomy.
* Patient who has the indication of Zoladex and has been prescribed Zoladex according to physician's judgement, irrespective of the inclusion in the study.
* Patient has been already prescribed Zoladex within 1 month after operation.

Exclusion Criteria:

* Have used hormone treatment prior to 3 months of recruitment.
* Involvement in the planning and conduct of the study (applies to both AstraZeneca staff or staff at the study site).
* Previous enrolment in the present study.

Primary outcomes:
measure: Symptom recurrence rate and total recurrence rate
timeFrame: 18 months
Secondary outcomes:
measure: Pregnancy rate
timeFrame: 18 months
measure: Zoladex administration time
timeFrame: 6 months
measure: Add-back therapy information
timeFrame: 18 months
Other outcomes:
Locations:
city: Hefei
country: China
facility: Research Site
state: Anhui
city: Beijing
country: China
facility: Research Site
state: Beijing
city: Guangzhou
country: China
facility: Research Site
state: Guangdong
city: Shenzhen
country: China
facility: Research Site
state: Guangdong
city: Harbin
country: China
facility: Research Site
state: Heilongjiang
city: Changsha
country: China
facility: Research Site
state: Hunan
city: Shenyang
country: China
facility: Research Site
state: Liaoning
city: Shanghai
country: China
facility: Research Site
state: Shanghai
city: Xi'an
country: China
facility: Research Site
state: Shanxi
city: Chengdu
country: China
facility: Research Site
state: Sichuan
city: Hangzhou
country: China
facility: Research Site
state: Zhejiang
Study officials:
affiliation: Peking University First Hospital
name: Zhou Yingfang
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01246596: Chronic Presence of Epstein Barr Virus in Epithelial Cells From Gingiva is Associated With Periodontitis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Chronic Periodontitis
Aggressive Periodontitis
Presence / Absence of EBV
Lead sponsor: Centre Hospitalier Universitaire de Nice
Sponsor class: OTHER
First posted: 2010-11-23
Enrollment: 23
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: The etiopathogenesis of periodontal disease results from complex interaction between infectious agents, mainly including bacteria, and host cellular and humoral immune responses. However it is thought that bacteria-induced pathogenesis is not sufficient alone to explain all biological and clinical features of the destructive periodontal disease. The main hypothesis is that herpesviruses, such as Epstein-Barr Virus, may participate as well by altering epithelial gingival cell biology and consequently may promote the initiation and progression of periodontitis.


Eligibility criteria: Inclusion Criteria:

* 10 patients affected by chronic periodontitis
* 10 patients affected by aggressive periodontitis
* 10 healthy patients (orthodontics extraction)
* Subject who have read and understood the information note relative under investigation and who have signed the informed consent
* major patient

Exclusion Criteria:

* Patient with no contre-indication to periodontal treatment
* Patient with serious blood disease
* Patient who exhibits systemic condition incompatible with realization of the study
* Patient treated with oral retinoids, bisphosphonates, oral anticoagulants and anticonvulsivants
* Patient who presents a buccal carcinoma treated with radiotherapy
* Patient who have received during the past 6 months: anti-inflammatory drugs, anti-cancerous or immunosuppressive chemiotherapy
* Patient who presents a linguistic or psychic incapacity to understand information

Primary outcomes:
measure: Percentage of gingival epithelial cells infected by EBV (by immunofluorescence and In situ Hybridization)
timeFrame: at time=0
Secondary outcomes:
measure: Epithelial tissue infected by EBV (by immunofluorescence and in situ hybridization)
timeFrame: at time = 0
measure: Presence / absence of latency and / or lytic proteins (by immunofluorescence and in situ hybridization)
timeFrame: at time = 0
Other outcomes:
Locations:
city: Nice
country: France
facility: Dr Severine VINCENT
Study officials:
affiliation: CHU de Nice Hôpital Saint Roch
name: Severine VINCENT, PH
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06869096: Chlorhexidine Gluconate Versus Saline for Flushing the Surgical Area During Colorectal Cancer Surgery
Official title: A Comparative Study of Chlorhexidine Versus Saline Irrigation of the Surgical Area During Colorectal Cancer Surgery: a Multicenter, Stratified Randomized Controlled Trial.
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Colorectal Cancer
Surgical Site Infection
Chlorhexidine
Complications
Lead sponsor: Nanchong Central Hospital
Sponsor class: OTHER_GOV
First posted: 2025-03-11
Enrollment: 532
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The aim of this study was to compare the effectiveness of chlorhexidine versus saline in flushing the surgical area during colorectal cancer surgery. The primary outcomes included surgical site infection, postoperative complication rates, et al.


Eligibility criteria: Inclusion Criteria:

1. Patients aged 18-85 years,
2. Patients with surgically resectable colorectal tumors confirmed by CT/MRI before surgery
3. All patients had a performance status score of 0 or 1 in the Eastern Tumor Cooperative group
4. American Society of Anesthesiology grade I-III

Exclusion Criteria:

1. The tumor may have distant metastasis
2. History of previous abdominal surgery
3. The patient has a history of other malignant tumors diagnosed in the past 5 years and has received radiotherapy and chemotherapy in the past
4. There are obvious contraindications to surgery (obvious abnormal liver and kidney function, pregnancy)
5. Participated in other clinical trials within the past 6 months

Primary outcomes:
measure: Number of participants with Surgical site infection within 30 days
timeFrame: 30 days
Secondary outcomes:
measure: Number of participants with Postoperative complication within 30 days
timeFrame: 30 days
Other outcomes:
Locations:
city: Nanchong
country: China
facility: Nanchong Central Hospital
state: Sichuan
Study officials:
References:
Clinical trial NCT02163096: A Study to Assess Benign Joint Hypermobility Syndrome in Children With a History of Wheezing or Asthma
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Benign Joint Hypermobility Syndrome
Wheezing
Asthma
Lead sponsor: University of Louisville
Sponsor class: OTHER
First posted: 2014-06-13
Enrollment: 23
Sex: ALL
Minimum age (years): 6
Maximum age (years): 16
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Children ages 6-16 in Primary Care Clinic and Pediatric Subspecialty Clinics of Pulmonary and Allergy/Immunology.

Brief summary: The purpose of this study is to assess benign joint hypermobility syndrome (BJHS) in children with a history of wheezing or asthma. BJHS is a common syndrome of joint and connective tissue laxity without any other rheumatologic disease. This assessment will be performed by using either method below depending upon if the child has a history of wheezing or severe asthma:

1. Determine the correlation, if there is an increased rate of BJHS in children with a history of wheezing as well as if there is an increased history of wheezing in children with BJHS; or
2. Determine asthma control, lung function and asthma exacerbations (a flare up or acute worsening of symptoms) in children with BJHS compared to children with asthma without BJHS, to assess if it BJHS is associated more with children with severe asthma.


Eligibility criteria: Inclusion Criteria:

* All children ages 6-16 with a history of wheezing or asthma

Exclusion Criteria:

* For subjects with a history of Wheezing: History of chronic lung disease or prematurity, chronic aspiration, congenital anomalies of the upper and lower airway, primary ciliary dyskinesia, cystic fibrosis, history of heart failure, immune deficiency, or any inflammatory arthritis.
* For Subjects with a history of Asthma: current acute respiratory exacerbation, history of chronic lung disease of prematurity, chronic aspiration, congenital anomalies of the upper or lower airway, primary ciliary dyskinesia, cystic fibrosis, restrictive lung disease, history of heart failure, immune deficiency, or inflammatory arthritis.

Primary outcomes:
measure: Determine correlation between BJHS and Wheezing/Asthma
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Louisville
country: United States
facility: University of Louisville - Sam Swope Kosair Charities Centre
state: Kentucky
city: Louisville
country: United States
facility: University of Louisville Allergy and Immunology
state: Kentucky
city: Louisville
country: United States
facility: University of Louisville Pediatric Pulmonology
state: Kentucky
Study officials:
References:
Clinical trial NCT01384396: A Clinical Study of KW-3357 in Patients With DIC
Official title: A Clinical Study of KW-3357 in Patients Diagnosed as Disseminated Intravascular Coagulation (DIC) by the Diagnostic Criteria for DIC Established by the Japanese Ministry of Health and Welfare
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Disseminated Intravascular Coagulation (DIC)
Lead sponsor: Kyowa Kirin Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2011-06-29
Enrollment: 15
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To evaluate the efficacy and safety of KW-3357 with concomitant use of heparin using multi-center, non-comparative, open-label method in patients diagnosed as disseminated intravascular coagulation (DIC) by the diagnostic criteria for DIC established by the Japanese Ministry of Health and Welfare.


Eligibility criteria: Inclusion Criteria:

* Diagnosed or suspected as DIC by the diagnostic criteria for DIC established by the Japanese Ministry of Health and Welfare
* Antithrombin activity \<= 70%
* Written informed consent from patient or guardian

Exclusion Criteria:

* Anamnesis or complication of serious drug allergy
* Serious liver disorder, such as fulminant hepatitis and decompensated cirrhosis
* Pregnant, nursing, or possibly pregnant woman
* Possibility for the promotion of bleeding by concomitant use of heparin

Primary outcomes:
measure: Safety
timeFrame: up to 6 days (or discontinuation)
measure: DIC resolution
timeFrame: 6 days (or discontinuation)
Secondary outcomes:
measure: DIC score
timeFrame: Screening, 2, 3, 4, 5, 6 days (or discontinuation)
measure: Mortality
timeFrame: 28 days
measure: Plasma antithrombin activity
timeFrame: Screening, 2, 3, 4, 5, 6 days (or discontinuation)
Other outcomes:
Locations:
city: Kanazawa
country: Japan
Study officials:
References:
Clinical trial NCT00921596: Cardiac Operation Under Totally Endoscope and Cardiopulmonary Bypass (CPB)
Official title: Cardiac Operation Under Totally Endoscope and Cardiopulmonary Bypass, a Single Center's Experience
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
PHASE2
Conditions: Congenital Heart Defects
Heart Valve Diseases
Keywords: Surgical Procedures, Cardiac
Minimally Invasive Surgical Procedures
Thoracoscopes
Cardiopulmonary Bypass
Lead sponsor: Xijing Hospital
Sponsor class: OTHER
First posted: 2009-06-16
Enrollment: 800
Sex: ALL
Minimum age (years): 2
Maximum age (years): 70
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Conventional cardiac operations are performed with median sternotomy, which is related to great wound, morbidities, longer duration in hospital and most significantly, cosmetic problems. The investigators invested a new minimally invasive cardiac operation method totally under video-endoscope and peripheral cardiopulmonary bypass. The investigators' hypothesis is that this new minimally method could provide better cosmetic effects to the patients, and also relate to shorter postoperative hospital stay and better recovery.


Eligibility criteria: Inclusion Criteria:

* congenital heart defects or heart valve diseases require surgical correction

Exclusion Criteria:

* Body weight \< 10kg
* committed with complex congenital heart defect
* anticipated to perform aortic valve repair or replacement
* anticipated to perform aorta repair or replacement
* committed with Femoral vessel diseases unable to perform femoral cannulation
* refuse to perform totally thoracoscope minimally invasive surgery

Primary outcomes:
measure: all cause mortality
timeFrame: one year
Secondary outcomes:
measure: all cause morbidity
timeFrame: one year
Other outcomes:
Locations:
city: Xi'an
country: China
facility: Xijing Hospital
state: Shannxi
Study officials:
affiliation: Xijing Hospital
name: Dinghua Yi, MD
role: STUDY_CHAIR
References:
Clinical trial NCT05078996: Treatment-related Quality of Life and Patient-Centred Care With Infertility
Official title: Patient-Centred Care and Treatment-related Quality of Life With Infertility
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Patient Centred Care
Compliance, Treatment
Infertility, Female
Quality of Life
Keywords: patient centred care
FertiQol
infertility
quality of life
nursing
Lead sponsor: Istanbul University - Cerrahpasa
Sponsor class: OTHER
First posted: 2021-10-15
Enrollment: 160
Sex: FEMALE
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Women who diagnosed with infertility

Brief summary: This study was conducted in a cross-sectional descriptive type with 160 infertile women who were treated in the IVF Clinic of a university hospital between July - October 2020 in order to evaluate the effect of patient-centered care approach in infertility on treatment-related quality of life. The data of the study were collected face to face through the "Introductory Information Form" "Patient Centered Care Form for Infertile Women" and "FertiQol Treatment Module".


Eligibility criteria: Inclusion Criteria:

* Diagnosed with infertility
* Has no commnunication problems

Exclusion Criteria:

* Communication problems (e.g language)
* Diagnosed by diseases with reproductive problems but not infertility

Primary outcomes:
measure: Treatment-related quality of life
timeFrame: from obtaining ethical permission to reaching sampling (approximately 6 months)
Secondary outcomes:
measure: Patient Centred Care
timeFrame: from obtaining ethical permission to reaching sampling (approximately 6 months)
Other outcomes:
Locations:
city: İstanbul
country: Turkey
facility: Elif Balkan
Study officials:
References:
Clinical trial NCT00448396: Evaluate the Effects of Patupilone on the Pharmacokinetics and Pharmacodynamics of Warfarin in Patients With Advanced Malignancies
Official title: An Open Label Phase I Study to Evaluate the Effects of Patupilone on the Pharmacokinetics and Pharmacodynamics of Warfarin in Patients With Advanced Malignancies
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Advanced Malignancies
Keywords: Cancer
EPO
Patupilone
Solid tumors
Advanced malignancies
Lead sponsor: Novartis
Sponsor class: INDUSTRY
First posted: 2007-03-16
Enrollment: 17
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To evaluate the effects of patupilone on the pharmacokinetics of warfarin in patients with advanced malignancies.


Eligibility criteria: Inclusion criteria

* Age ≥ 18 years of age
* Life expectancy ≥3 months
* Histologically documented advanced solid tumors which have progressed after standard systemic therapy or for which standard systemic therapy does not exist
* Agents containing warfarin or heparin must be discontinued 7 days prior to enrollment in the study

Exclusion criteria

* History of/or active bleeding disorders
* Known hypersensitivity to warfarin or related compounds
* The use of vitamin K
* Central lines that require anticoagulant maintenance
* The use of agents containing warfarin and heparin
* Known diagnosis of human immunodeficiency virus (HIV) infection, hepatitis Other protocol-defined inclusion/exclusion criteria may apply

Primary outcomes:
measure: To evaluate the effects of patupilone on the pharmacokinetics of warfarin in patients with advanced malignancies.
Secondary outcomes:
measure: To evaluate the effects of patupilone on the pharmacodynamics of warfarin in patients with advanced malignancies.
measure: Safety and tolerability of patupilone when administered concomitantly with warfarin in patients with advanced malignancies will be assessed by AE's, SAE's and safety labs.
Other outcomes:
Locations:
city: San Antonio
country: United States
state: Texas
Study officials:
affiliation: Novartis Pharmaceuticals
name: Novartis Pharmaceuticals
role: STUDY_CHAIR
References: